Overview

A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

Definition: This study will compare the drug GEMZAR to a combination of GEMZAR plus ALIMTA for the treatment of cancer of the pancreas. Patients may be able to participate in this study if they have cancer in their pancreas that cannot be removed by surgery OR that has spread to a new site in their body.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Gemcitabine
Pancreatin
Pancrelipase
Pemetrexed